The aforementioned weight loss interventions were also associated with improvements in NAFLD biomarkers, including alanine aminotransferase (-9.81 U/L; 95% CI, -13.12 to -6.50), histologically or radiologically measured liver steatosis (standardized mean difference: -1.48; 95% CI, -2.27 to -0.70), histologic NAFLD activity score (-0.92; 95% CI, -1.75 to -0.09), and presence of nonalcoholic steatohepatitis (odds ratio, 0.14; 95% CI, 0.04-0.49). Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.